Comissões

Clarissa Mathias
Médica oncologista do NOB/Oncoclínicas, chair do Conselho Internacional da Sociedade Americana de Oncologia Clínica (ASCO), presidente da Sociedade Brasileira de Oncologia Clínica (SBOC).

Sergio Simon
Faculdade de Medicina da Universidade de SP, 1973; especialização em Clínica Médica, Hematologia e Oncologia Clínica nos Estados Unidos 1974-1980; doutorado pela Universidade de São Paulo, 2003; professor assistente de Oncologia, UNIFESP 2008-2013; oncologista clínico do Hospital Israelita Albert Einstein e do Centro Paulista de Oncologia; membro da SBOC, ASCO e ESMO.

Paulo Marcelo Gehm Hoff
Médico formado pela Universidade de Brasília (1991); doutorado e livre docência em Oncologia pela Faculdade de Medicina da Universidade de São Paulo, onde é professor titular; Fellowship em Hematologia e Oncologia no MD Anderson Cancer Center. Atualmente é diretor-geral do Instituto do Câncer de São Paulo “Octávio Frias de Oliveira” e membro dos Conselhos Diretores da ASCO e do Hospital das Clínicas.

Carlos Gil Moreira Ferreira
Carlos Gil Ferreira, MD, PhD. Oncologista clínico, doutor em oncologia experimental pela Vrije Universiteit Medical Center, Amsterdã, Holanda. Presidente e diretor científico do Instituto Oncoclínicas.

Manuel Hidalgo
Manuel Hidalgo, M.D., Ph.D. is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital. He is also the Hugh E. Luckey Distinguished Professor of Medicine at Weill Cornell Medical Collge. Dr. Hidalgo received his MD degree from the University of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health Science Center in San Antonio. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio, TX. Prior to this position he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to be Director of the Gastrointestinal Oncology Programm at the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor of Oncology. In 2009 he became Director of the Clinical Research Program at the Speanish National Cancer Center and Vicedirector of Translational Research in 2011. In 2015 he became the Chief of the Division of Hematology and Oncology anf Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the used of Avatar mouse models for cancer research and recently contributed to the development and approval of nab-paclitaxel for pancreatic cancer treatmemt. His current work focuses on strategies for personalize medicine and inmmunotherapy in pancreatic cancer.